We would love to hear your thoughts about our site and services, please take our survey here.
Sellers should take a long look in the mirror with this one!!!!!! feeling jackpot hit? it will be a £billion company, pay dividends for many years to come start of my retirement I think GLA happy Christmas x
Can’t sell locked in to the bitter end
Mon, 12th Sep 2022 07:00
RNS Number : 0223Z
Sareum Holdings PLC
12 September 2022
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum notes the US FDA approval of Sotyktu™ (deucravacitinib), for Moderate-to-Severe Plaque Psoriasis, the first TYK2 inhibitor to gain FDA approval
Cambridge, UK, 12 September 2022 - Sareum Holdings plc (AIM: SAR), a clinical stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, notes the announcement from Bristol Myers Squibb (BMS) that the US Food and Drug Administration (FDA) has approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
This announcement supports Sareum's confidence in its broader portfolio of TYK2/JAK1 inhibitors focused on autoimmune disease.
This is the first approval by the FDA of a medicine based on TYK2, a member of the JAK cell signalling family. Sareum believes it provides clinical validation for this class of therapeutic, and for the broader TYK2/JAK1 signalling family, which underpins Sareum's clinical portfolio.
The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases.
The Sotyktu approval is based on a pivotal Phase 3 study of deucravacitinib which demonstrated superior efficacy against placebo and standard of care. It is also encouraging to note that deucravacitinib was well tolerated in the Phase 3 study. Unlike some other medicines in the JAK inhibitor class, the FDA is not requiring boxed warnings for deucravacitinib around the heightened risk of serious heart-related events.
"We're encouraged that the FDA has approved Sotyktu (deucravacitinib)," said Tim Mitchell, CEO of Sareum. "We believe this validates the potential of this new therapeutic class and supports our own growing confidence around our lead programme and our broader portfolio of TYK2/JAK1 inhibitors
"TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis. Sareum has submitted a Clinical Trial Authorisation (CTA) to the UK's Medicines and Healthcare Products Regulatory Agency to initiate a clinical trial of SDC-1801, with an initial focus on psoriasis, and hopes to begin dosing patients in 2023, subject to regulatory approvals."
Sareum will update on the regulatory progress of SDC-1801 in due course.
Bristol Myers Squibb's announcement can be found here.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO
01223 497700
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman
020 7409 3494
Peel Hunt LLP (Joint Co
That’s wonderful Ahfam3 now let’s see about that Clinical Trial Application as this could as popular as a male contraceptive!! All hocus-pocus fairy dust until the proof results from eating the puddling!! But bravo to your endless posting of data just need SAREUM to headline and not be a mere coincidence The reminding of a poster that hopefully has his
Yacht moored you are but endlessly hoping this turns out to be a slight delay due to a jobs worth spotty twat on minimum wage wagging one’s finger. Hopefully deals to be done sooner rather than later as the delay was hard to swallow. Come on SAR
That’s lovely lovepeceandharmory I will start thinking positive for the preclinical acquisition of this rollercoaster that is SAR. In fact I will start meditating right away. After all it’s not completely out of the question as it is SARs business model..The secret will be out soon!!!!! AGM 16th gla
Yes strange??? how many AIM companies would pine for £1.6 billion government contract???? very under valued here
Tick tok tick tok
The share the BOD forgot they had.., Dr Frankenstein you might have to stick your probes somewhere??????
I’m beginning to think SAR are at the later stages of a preclinical buyout why else would they withhold price sensitive information?? Spooky!!
CAPX get the share price out of here no takeover bids below 50p please
CAP-XX Limited
("CAP-XX" or the "Company")
Energous and CAP-XX Partner to Develop Battery-Free Wirelessly Powered IoT devices for a Range of IoT Applications
CAP-XX's supercapacitors combined with Energous' wireless power technology to enable maintenance-free IoT devices that do not require battery replacement
SAN JOSE, Calif. & SYDNEY, Australia - Energous Corporation (NASDAQ: WATT), a leading developer of RF-based charging for wireless power networks, and CAP-XX Limited (LSE:CPX) - the leading manufacturer of ultra-thin prismatic, cylindrical, and Lithium-Ion supercapacitors - today announced a partnership to develop solutions that combine Energous' WattUp technology with CAP-XX's high-performance supercapacitors. The companies are partnering to pave the way for battery free Internet of Things (IoT) devices powered by Energous's wireless power technology and CAP-XX's long life supercapacitors.
"One of the critical challenges hindering large-scale IoT deployment is the problem of constant battery replacement in each of those IoT devices," said Cesar Johnston, CEO of Energous. "We are partnering with CAP-XX to eliminate battery replacements and reduce cost of maintenance, thus enabling IoT devices at scale."
CAP-XX is a leader in the design and manufacture of thin, flat supercapacitors used in portable and small-scale electronic devices. Its supercapacitors feature high power density and high energy storage capacity in a space-efficient prismatic package, essential in internet-connected devices deployed in space-constrained electronics applications. CAP-XX's thinnest supercapacitor is 0.4mm thick, about half the thickness of a credit card. CAP-XX supercapacitors provide peak power support for pulsed loads, secure power back-up for mission critical applications, and battery-independent power storage while also reducing the weight, cost and size of batteries, component cost and number and environmental impact.
"The combination of our supercapacitors with Energous' WattUp over-the-air wireless power technology will provide a much-needed solution to one of IoT's main headaches: the need for constant battery replacement," said Anthony Kongats, CEO at CAP-XX. "We are excited to work closely with Energous to develop a groundbreaking solution for the fast-growing ecosystem of IoT devices."
I agree cheap as chips these shares
Fill your boots time methinks?
This is HOPEFULLY stupid thought but is there any evidence they have applied for CTA of 1801 in the first place.. Has anyone seen the CTA log number JUST ASKING
Formal letter of non acceptance surely should have arrived. By now ???
8th Nov RNS
Whilst the Company has yet to receive a formal letter of non-acceptance, the MHRA has indicated that it seeks a review by the UK Good Laboratory Practice (GLP) Monitoring Authority, or further support, of the non-clinical data submitted as part of the application to approve the clinical study. Sareum and its advisors are seeking additional clarification from the MHRA and will provide an update on next steps for resubmission as soon as possible.
Change of wording from sar 737 update from Sierra intend to return to will return.. I like it looking forward to positive progress on 1801 Clinical trial application
Check out Harland & Wolff (harl)
All I know about the price is, in another dimension where GSK took on 737 and the CTA for 1801 was granted the price spiked other £10 for which I got out and was never to be heard of again.. o that was what was sure to happen here funk me.. I suppose I will go back to reading the Walford Gazette?!?!?!?
Should have said cigarettes
I hope your right SOD and HOT but investing in this prospective health care company has got me back on the ***s!!!!!
I don’t think BOD will stabilise the share as I feel this is a war between the private and the institutional investor for voting power. I can’t see them making a mistake of such magnitude??? Once this is resolved more than likely investment will be made available as money rules everyone and everything. But I would love a RNS stating problem solved CTA granted obviously